FAB Pharma: Narrower is Better

FAB Pharma S.A.S. believes that by targeting a new mechanism of action in the fatty acid biosynthesis pathway, it can develop narrow-spectrum antibiotics against methicillin-resistant Staphylococcus aureus with a much better side effect profile than existing drugs.

FAB spun out of Mutabilis S.A. in July 2009 with lead compound Fab-001. The company was to announce on Monday that it started

Read the full 597 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE